Phase I Study on the Impact of Erythromycin-Mediated CYP3A4/5 Inhibition on CHF6001 Pharmacokinetics in Healthy Volunteers

The primary objective of this phase I trial is to investigate the effect of **Erythromycin** on the pharmacokinetics of **CHF6001** in healthy volunteers. This study aims to assess how the inhibition of **CYP3A4/5** by **Erythromycin** influences the absorption, metabolism, and elimination of **CHF6001**. Understanding these interactions is clinically relevant as it may inform dosing strategies and safety considerations for patients who may be co-administered these compounds. No secondary objectives are provided for this study.

The clinical trial involves a study population of **healthy volunteers** to assess the effect of CYP3A4/5 inhibition by Erythromycin on the pharmacokinetics of CHF6001. The trial includes both male and female participants, with an age range categorized under code "3," which typically represents adults. The trial population selection criteria and the total number of participants have not been disclosed by the sponsor. Participants are expected to be in good general health, as the study focuses on healthy individuals. The trial does not specify any particular lifestyle considerations such as diet or physical activity. The inclusion of a vulnerable population is noted, although specific details regarding this aspect are not provided.

The clinical trial is designed as a **phase I** study to evaluate the effect of **erythromycin** on the pharmacokinetics of CHF6001 in healthy volunteers. This trial will assess the impact of CYP3A4/5 inhibition by erythromycin on the absorption, metabolism, and elimination of CHF6001. The study is structured as a randomized, double-blind, controlled trial, ensuring that neither the participants nor the investigators are aware of the treatment assignments, thereby minimizing bias. The trial is expected to commence on February 15, 2024, with an estimated completion date of July 27, 2024, indicating a total duration of approximately five months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This initial visit will involve a comprehensive assessment, including medical history, physical examination, and laboratory tests. Following successful screening, participants will be randomized and begin the treatment phase, which will include multiple follow-up visits to monitor safety, tolerability, and pharmacokinetic parameters. These visits will involve blood sampling and other assessments as per the study protocol. The end-of-study visit will occur after the final treatment period, where a thorough evaluation will be conducted to ensure participant safety and collect final data.

The expected length of participant involvement is contingent upon the study schedule, with each participant anticipated to be involved for the duration of the trial. However, conditions such as adverse events, non-compliance with the study protocol, or withdrawal of consent may lead to early termination from the study. The trial is conducted in accordance with ethical guidelines and regulatory requirements, ensuring the safety and well-being of all participants throughout the study duration.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of these details limits the ability to describe the treatment regimen comprehensively.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to begin recruitment on February 15, 2024, with an estimated end date of July 27, 2024. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The methods and schedule for measuring, collecting, and analyzing these efficacy parameters are not specified. The trial will adhere to the standard protocols for Phase 3 studies, ensuring rigorous assessment of the treatment's effectiveness. The trial's design and execution will follow established clinical guidelines to ensure the reliability and validity of the efficacy data collected.